×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Cure Connections

Before Dr. Eskander turns to the future treatment of ovarian cancer, participants consider how the treatment journey can affect caregivers.
A breakdown of the support networks patients can build and rely on as they receive treatment for ovarian cancer.
Considerations for maintaining mental and emotional well-being while going through a diagnosis of and treatment for ovarian cancer.
Doña Harman shares how stigma surrounding cancer affected the reactions of some around her, while others offered their support.
More

Cure Expert Connections

The importance of support networks and a multidisciplinary team when managing advanced-stage renal cancer.
A discussion regarding the significance of dose modification to mitigate toxicity burden.
Steven Gallant, a stage 4 renal cell cancer survivor, discusses how he managed the toxicities of cabozantinib frontline therapy.
A discussion regarding the frontline treatment options for aggressive renal cell cancer, and the factors considered in choosing the appropriate therapy.
More

Cure TV

SPONSORED CONTENT
Optune caregivers offer advice and support to fellow caregivers.
Dr. Sara Hurvitz
When making treatment decisions in breast cancer, patient concerns about how each treatment will affect their daily life — and their disease stage — have an important role to play, according to Dr. Sara Hurvitz.
Dr. Sara Hurvitz
The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to one expert.
Dr. Arash Rezazadeh Kalebasty
When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.
More
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×